Publications by authors named "Claes Karlsson"

Claim this Profile
B
Bridging the Divide: A Review on the Implementation of Personalized Cancer Medicine.
Michele Masucci, Claes Karlsson, Lennart Blomqvist, Ingemar Ernberg

J Pers Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.
David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid, Jorrit Boekel, Adria Lopez-Fernandez, Claes Karlsson

Nat Cancer· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.
David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid, Jorrit Boekel, Adria Lopez-Fernandez, Claes Karlsson

Nat Cancer· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.
Maria Winqvist, Per-Ola Andersson, Anna Asklid, Karin Karlsson, Claes Karlsson

Haematologica· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013.
Sandra Eketorp Sylvan, Anna Asklid, Hemming Johansson, Jenny Klintman, Jenny Bjellvi, Claes Karlsson, Karin Karlsson

Haematologica· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
Maria Winqvist, Anna Asklid, P O Andersson, Karin Karlsson, Claes Karlsson

Haematologica· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Asher Chanan-Khan, Paula Cramer, Fatih Demirkan, Graeme Fraser, Rodrigo Santucci Silva, Claes Karlsson

Lancet Oncol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region.
Sandra Eketorp Sylvan, Lotta Hansson, Claes Karlsson, Stefan Norin, Jeanette Lundin

Leuk Lymphoma· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression.
Sandra Eketorp Sylvan, Eva Rossmann, Fariba Mozaffari, Anna Porwit, Stefan Norin, Claes Karlsson

Br J Haematol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia.
Claes Karlsson, Jeanette Lundin, Eva Kimby, Ben Kennedy, Paul Moreton

Br J Haematol· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.
Anders Osterborg, Claes Karlsson, Jeanette Lundin

Curr Hematol Malig Rep· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia.
Mohammad Reza Rezvany, Mahmood Jeddi Tehrani, Claes Karlsson, Jeanette Lundin, Hodjattallah Rabbani

Br J Haematol· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia.
Jeanette Lundin, Claes Karlsson, Fredrik Celsing

Med Oncol· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strategies in the management of alemtuzumab-related side effects.
Anders Osterborg, Claes Karlsson, Jeanette Lundin, Eva Kimby, Håkan Mellstedt

Semin Oncol· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis